Dupilumab: a potential new treatment for severe asthma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper.Allergy · 2022
   Article
2. The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions.Current research in immunology · 2022
   Review
3. The multifaceted roles of FOXM1 in pulmonary disease.Cell communication and signaling : CCS · 2019
   Review
4. Current State and Future of Biologic Therapies in the Treatment of Asthma in Children.Pediatric allergy, immunology, and pulmonology · 2018
   Review
5. Innovative Therapies for Severe Asthma.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2017
   Review
6. Emerging Endotypes of Chronic Rhinosinusitis and Its Application to Precision Medicine.Allergy, asthma & immunology research · 2017
   Review
7. Dupilumab in the management of moderate-to-severe asthma: the data so far.Therapeutics and clinical risk management · 2017
   Review

Corrections and comments

• Comment on
  Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.2016

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as